Drug Patents Expiring in 2028
1. List of Abilify Mycite Kit drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9119554 | OTSUKA | Pharma-informatics system |
Dec, 2028
(5 years from now) | |
Drugs and Companies using ARIPIPRAZOLE ingredient
Market Authorisation Date: 13 November, 2017
Treatment: NA
Dosage: TABLET;ORAL
ABILIFY MYCITE KIT family patents
64
United States
18
Japan
11
European Union
9
Canada
9
Israel
7
China
7
Taiwan, Province of China
6
Hong Kong
6
Australia
4
Russia
4
Brazil
4
Mexico
4
Korea, Republic of
3
India
2
South Africa
2
Ukraine
2
Denmark
1
Portugal
1
Spain
1
Cyprus
1
Slovenia
1
Poland
2. List of Acuvail drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9192571 | ALLERGAN | Ketorolac tromethamine compositions for treating or preventing ocular pain |
Mar, 2028
(4 years from now) | |
| US8512717 | ALLERGAN | Compositions for delivery of therapeutics into the eyes and methods for making and using same |
Mar, 2028
(4 years from now) | |
Drugs and Companies using KETOROLAC TROMETHAMINE ingredient
Market Authorisation Date: 22 July, 2009
Treatment: NA
Dosage: SOLUTION/DROPS;OPHTHALMIC
ACUVAIL family patents
30
United States
6
European Union
5
Spain
5
Australia
4
Japan
4
Canada
4
Poland
3
China
3
Denmark
2
Brazil
2
New Zealand
2
Austria
2
Korea, Republic of
1
Germany
1
Malaysia
1
Russia
1
Croatia
1
Colombia
1
Mexico
1
Hong Kong
1
South Africa
1
Slovenia
1
Hungary
1
Ukraine
1
Israel
3. List of Acuvue Theravision With Ketotifen drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9474746 | JOHNSON JOHNSON VISN | Methods for stabilizing oxidatively unstable compositions |
Mar, 2028
(5 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Product (NP) | Feb 25, 2025 |
Drugs and Companies using KETOTIFEN FUMARATE ingredient
Market Authorisation Date: 25 February, 2022
Treatment: NA
Dosage: DRUG-ELUTING CONTACT LENS ;OPHTHALMIC
ACUVUE THERAVISION WITH KETOTIFEN family patents
6
United States
3
Korea, Republic of
2
Hong Kong
2
Russia
2
Canada
1
Taiwan, Province of China
1
Japan
1
Australia
1
Argentina
1
China
1
Brazil
1
European Union
4. List of Addyi drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7151103 | SPROUT PHARMS | Method of treating female hypoactive sexual desire disorder with flibanserin |
May, 2028
(5 years from now) | |
Drugs and Companies using FLIBANSERIN ingredient
Market Authorisation Date: 18 August, 2015
Treatment: Use of flibanserin or a pharmaceutically acceptable acid addition salt thereof to treat hypoactive sexual desire disorder (hsdd)
Dosage: TABLET;ORAL
ADDYI family patents
13
United States
4
China
4
European Union
3
Korea, Republic of
3
Japan
2
Argentina
1
Portugal
1
Germany
1
Malaysia
1
Spain
1
Brazil
1
Croatia
1
New Zealand
1
Norway
1
Austria
1
Mexico
1
EA
1
South Africa
1
Canada
1
Hungary
1
Slovenia
1
ME
1
Yugoslavia
1
Ukraine
1
Israel
1
Poland
1
Australia
1
Ecuador
1
Denmark
5. List of Afinitor drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9006224 | NOVARTIS | Neuroendocrine tumor treatment |
Jul, 2028
(5 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Feb 26, 2023 |
Drugs and Companies using EVEROLIMUS ingredient
Market Authorisation Date: 30 March, 2009
Treatment: Treatment of patients with progessive neuroendocrine tumors of pancreatic origin (pnet) that are unresectable, locally advanced or metastatic
Dosage: TABLET;ORAL
AFINITOR family patents
6
United Kingdom
5
European Union
4
New Zealand
4
Norway
4
United States
3
Japan
2
China
2
Korea, Republic of
2
Canada
2
Australia
1
Portugal
1
Russia
1
Spain
1
Brazil
1
Croatia
1
Morocco
1
Hong Kong
1
Tunisia
1
South Africa
1
Cyprus
1
Slovenia
1
Israel
1
Poland
1
Denmark
6. List of Airduo Digihaler drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8651103 | TEVA PHARM | Dry powder inhalation apparatus |
Mar, 2028
(5 years from now) | |
|
US8651103
(Pediatric) | TEVA PHARM | Dry powder inhalation apparatus |
Sep, 2028
(5 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| M (M) | Jul 9, 2024 |
| Pediatric Exclusivity (PED) | Jan 9, 2025 |
Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient
Market Authorisation Date: 27 January, 2017
Treatment: NA
Dosage: POWDER;INHALATION
AIRDUO DIGIHALER family patents
5
United States
1
United Kingdom
1
Portugal
1
Germany
1
Slovenia
1
Japan
1
Poland
1
Australia
1
Denmark
1
Austria
1
Spain
1
Canada
1
Cyprus
1
European Union
7. List of Alvesco drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8371292 | COVIS | Use of ciclesonide for the treatment of respiratory diseases |
Feb, 2028
(4 years from now) | |
Drugs and Companies using CICLESONIDE ingredient
Market Authorisation Date: 10 January, 2008
Treatment: Maintenance treatment of asthma as prophylactic therapy in adult and adolescent patients 12 years of age and older. patent claims method for treating a respiratory disease in a child
Dosage: AEROSOL, METERED;INHALATION
ALVESCO family patents
6
United States
2
Japan
2
European Union
1
Portugal
1
Slovenia
1
Croatia
1
Poland
1
Australia
1
Denmark
1
Canada
1
Spain
1
Cyprus
8. List of Ameluz drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11540981 | BIOFRONTERA | Nanoemulsion formulation with improved stability and cell penetration |
Feb, 2028
(4 years from now) | |
Drugs and Companies using AMINOLEVULINIC ACID HYDROCHLORIDE ingredient
Market Authorisation Date: 10 May, 2016
Treatment: NA
Dosage: GEL;TOPICAL
9. List of Amvuttra drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US10131907 | ALNYLAM PHARMS INC | Glycoconjugates of RNA interference agents |
Aug, 2028
(5 years from now) | |
| US10806791 | ALNYLAM PHARMS INC | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2028
(5 years from now) | |
| US8828956 | ALNYLAM PHARMS INC | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2028
(5 years from now) | |
| US9370581 | ALNYLAM PHARMS INC | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2028
(5 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jun 13, 2027 |
Drugs and Companies using VUTRISIRAN ingredient
NCE-1 date: 2026-06-13
Market Authorisation Date: 13 June, 2022
Treatment: Amvuttra is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults
Dosage: SOLUTION;SUBCUTANEOUS
AMVUTTRA family patents
30
United States
12
Japan
8
Canada
7
European Union
4
Australia
1
China
10. List of Angiomax drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7598343 | SANDOZ INC | Pharmaceutical formulations of bivalirudin and processes of making the same |
Jul, 2028
(5 years from now) | |
| US7582727 | SANDOZ INC | Pharmaceutical formulations of bivalirudin and processes of making the same |
Jul, 2028
(5 years from now) | |
Drugs and Companies using BIVALIRUDIN ingredient
Market Authorisation Date: 15 December, 2000
Treatment: NA
Dosage: INJECTABLE;INTRAVENOUS
11. List of Anoro Ellipta drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8161968 | GLAXOSMITHKLINE | Medicament dispenser |
Feb, 2028
(4 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| M (M) | Jun 9, 2022 |
Drugs and Companies using UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE ingredient
Market Authorisation Date: 18 December, 2013
Treatment: NA
Dosage: POWDER;INHALATION
ANORO ELLIPTA family patents
2
European Union
1
United Kingdom
1
Germany
1
Hong Kong
1
Poland
1
United States
1
Australia
1
Brazil
1
Mexico
1
Canada
1
Denmark
1
Austria
1
South Africa
1
Spain
1
Japan
1
China
1
Cyprus
12. List of Aptiom drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9763954 | SUNOVION PHARMS INC | Therapeutical uses of eslicarbazepine |
Sep, 2028
(5 years from now) | |
| US9566244 | SUNOVION PHARMS INC | Pharmaceutical composition comprising licarbazepine acetate |
Oct, 2028
(5 years from now) | |
| US10912781 | SUNOVION PHARMS INC | Pharmaceutical composition comprising licarbazepine acetate |
Oct, 2028
(5 years from now) | |
Drugs and Companies using ESLICARBAZEPINE ACETATE ingredient
Market Authorisation Date: 08 November, 2013
Treatment: Treatment of partial-onset seizures in patients with epilepsy who have been previously treated with oxcarbazepine
Dosage: TABLET;ORAL
APTIOM family patents
10
United States
5
Portugal
5
Japan
4
Korea, Republic of
4
European Union
3
Spain
2
Russia
2
Brazil
2
Croatia
2
Argentina
2
Mexico
2
China
2
Lithuania
2
Canada
2
Cyprus
2
Hungary
2
Slovenia
2
Ukraine
2
Poland
2
Australia
2
RS
2
Denmark
1
United Kingdom
1
New Zealand
1
South Africa
13. List of Arcapta Neohaler drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8479730 | NOVARTIS | Inhaler device |
Oct, 2028
(5 years from now) | |
Drugs and Companies using INDACATEROL MALEATE ingredient
Market Authorisation Date: 01 July, 2011
Treatment: NA
Dosage: POWDER;INHALATION
ARCAPTA NEOHALER family patents
2
Japan
2
European Union
1
United Kingdom
1
Portugal
1
Germany
1
Malaysia
1
Russia
1
Spain
1
Brazil
1
New Zealand
1
Norway
1
Mexico
1
Argentina
1
Austria
1
Morocco
1
Peru
1
China
1
Taiwan, Province of China
1
Korea, Republic of
1
Hong Kong
1
United States
1
Tunisia
1
South Africa
1
Canada
1
Cyprus
1
Slovenia
1
Israel
1
Poland
1
Australia
1
Ecuador
1
Denmark
14. List of Arikayce Kit drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8226975 | INSMED INC | Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof |
Aug, 2028
(5 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Sep 28, 2025 |
| Generating Antibiotic Incentives Now (GAIN) | Sep 28, 2030 |
Drugs and Companies using AMIKACIN SULFATE ingredient
Market Authorisation Date: 28 September, 2018
Treatment: NA
Dosage: SUSPENSION, LIPOSOMAL;INHALATION
ARIKAYCE KIT family patents
18
United States
4
European Union
3
Canada
2
Spain
1
Portugal
1
Hungary
1
Japan
1
Poland
1
Australia
1
Denmark
1
Lithuania
1
Cyprus
15. List of Armonair Digihaler drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8651103 | TEVA PHARM | Dry powder inhalation apparatus |
Mar, 2028
(5 years from now) | |
|
US8651103
(Pediatric) | TEVA PHARM | Dry powder inhalation apparatus |
Sep, 2028
(5 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Patient Population (NPP) | Jul 9, 2024 |
| New Strength (NS) | Jul 9, 2024 |
| Pediatric Exclusivity (PED) | Jan 9, 2025 |
Drugs and Companies using FLUTICASONE PROPIONATE ingredient
Market Authorisation Date: 27 January, 2017
Treatment: NA
Dosage: POWDER;INHALATION
ARMONAIR DIGIHALER family patents
5
United States
1
United Kingdom
1
Portugal
1
Germany
1
Slovenia
1
Japan
1
Poland
1
Australia
1
Denmark
1
Austria
1
Spain
1
Canada
1
Cyprus
1
European Union
16. List of Arnuity Ellipta drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8161968 | GLAXOSMITHKLINE | Medicament dispenser |
Feb, 2028
(4 years from now) | |
Drugs and Companies using FLUTICASONE FUROATE ingredient
Market Authorisation Date: 20 August, 2014
Treatment: NA
Dosage: POWDER;INHALATION
ARNUITY ELLIPTA family patents
2
European Union
1
United Kingdom
1
Germany
1
Hong Kong
1
Poland
1
United States
1
Australia
1
Brazil
1
Mexico
1
Canada
1
Denmark
1
Austria
1
South Africa
1
Spain
1
Japan
1
China
1
Cyprus
17. List of Astepro drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8071073 | MYLAN SPECIALITY LP | Compositions comprising azelastine and methods of use thereof |
Jun, 2028
(5 years from now) | |
Drugs and Companies using AZELASTINE HYDROCHLORIDE ingredient
Market Authorisation Date: 15 October, 2008
Treatment: NA
Dosage: SPRAY, METERED;NASAL
ASTEPRO family patents
9
United States
4
European Union
3
Portugal
3
Spain
3
Korea, Republic of
3
Lithuania
3
Slovenia
3
Poland
3
Australia
3
Denmark
2
Mexico
2
Japan
2
Hungary
2
Israel
1
Turkey
1
Brazil
1
Croatia
1
New Zealand
1
China
1
Hong Kong
1
South Africa
1
Canada
1
Cyprus
1
RS
18. List of Astepro Allergy drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8071073 | BAYER HLTHCARE | Compositions comprising azelastine and methods of use thereof |
Jun, 2028
(5 years from now) | |
Drugs and Companies using AZELASTINE HYDROCHLORIDE ingredient
Market Authorisation Date: 17 June, 2021
Treatment: NA
Dosage: SPRAY, METERED;NASAL
ASTEPRO ALLERGY family patents
9
United States
4
European Union
3
Portugal
3
Spain
3
Korea, Republic of
3
Lithuania
3
Slovenia
3
Poland
3
Australia
3
Denmark
2
Mexico
2
Japan
2
Hungary
2
Israel
1
Turkey
1
Brazil
1
Croatia
1
New Zealand
1
China
1
Hong Kong
1
South Africa
1
Canada
1
Cyprus
1
RS
19. List of Atelvia drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7645460 | APIL | Dosage forms of risedronate |
Jan, 2028
(4 years from now) | |
| US7645459 | APIL | Dosage forms of bisphosphonates |
Jan, 2028
(4 years from now) | |
Drugs and Companies using RISEDRONATE SODIUM ingredient
Market Authorisation Date: 08 October, 2010
Treatment: Treatment of osteoporosis in postmenopausal women
Dosage: TABLET, DELAYED RELEASE;ORAL
ATELVIA family patents
19
United States
7
Korea, Republic of
5
Japan
4
China
4
European Union
3
Portugal
3
Spain
3
New Zealand
3
Canada
3
Australia
2
Russia
2
Brazil
2
San Marino
2
Norway
2
Argentina
2
Mexico
2
Morocco
2
Taiwan, Province of China
2
Israel
2
Poland
2
Denmark
1
Germany
1
Malaysia
1
Croatia
1
Austria
1
Peru
1
Hong Kong
1
India
1
South Africa
1
Cyprus
1
Slovenia
1
Hungary
1
RS
20. List of Auvi-q drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7947017 | KALEO INC | Devices, systems and methods for medicament delivery |
Mar, 2028
(4 years from now) | |
| US7749194 | KALEO INC | Devices, systems, and methods for medicament delivery |
Oct, 2028
(5 years from now) | |
| US8231573 | KALEO INC | Medicament delivery device having an electronic circuit system |
Nov, 2028
(5 years from now) | |
Drugs and Companies using EPINEPHRINE ingredient
Market Authorisation Date: 10 August, 2012
Treatment: NA
Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS
AUVI-Q family patents
79
United States
15
Canada
14
United Kingdom
8
Japan
8
European Union
7
Australia
4
New Zealand
4
Mexico
4
China
3
Israel
3
Denmark
3
Spain
2
Hong Kong
2
Poland
21. List of Bevyxxa drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8557852 | PORTOLA PHARMS INC | Methods of using crystalline forms of a salt of a factor Xa inhibitor |
Sep, 2028
(5 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jun 23, 2022 |
Drugs and Companies using BETRIXABAN ingredient
NCE-1 date: 2021-06-23
Market Authorisation Date: 23 June, 2017
Treatment: Prophylaxis of deep vein thrombosis (dvt); Prophylaxis of venous thrombosis
Dosage: CAPSULE;ORAL
BEVYXXA family patents
9
United States
2
New Zealand
2
Argentina
2
Peru
2
China
2
Japan
2
European Union
1
Portugal
1
Russia
1
Spain
1
Brazil
1
Austria
1
Taiwan, Province of China
1
Korea, Republic of
1
Hong Kong
1
South Africa
1
Canada
1
Israel
1
Australia
1
Denmark
22. List of Brenzavvy drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8802637 | THERACOSBIO | Benzylbenzene derivatives and methods of use |
Aug, 2028
(5 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8106021 | THERACOSBIO | Benzylbenzene derivatives and methods of use |
Aug, 2028
(5 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jan 20, 2028 |
Drugs and Companies using BEXAGLIFLOZIN ingredient
NCE-1 date: 2027-01-20
Market Authorisation Date: 20 January, 2023
Treatment: An adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes
Dosage: TABLET;ORAL
23. List of Breo Ellipta drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8161968 | GLAXO GRP LTD | Medicament dispenser |
Feb, 2028
(4 years from now) | |
Drugs and Companies using FLUTICASONE FUROATE; VILANTEROL TRIFENATATE ingredient
Market Authorisation Date: 10 May, 2013
Treatment: NA
Dosage: POWDER;INHALATION
BREO ELLIPTA family patents
2
European Union
1
United Kingdom
1
Germany
1
Hong Kong
1
Poland
1
United States
1
Australia
1
Brazil
1
Mexico
1
Canada
1
Denmark
1
Austria
1
South Africa
1
Spain
1
Japan
1
China
1
Cyprus
24. List of Bydureon drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8216180 | ASTRAZENECA AB | Administering apparatus with functional drive element |
Jan, 2028
(4 years from now) | |
| US8361972 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Mar, 2028
(5 years from now) | |
| US9320853 | ASTRAZENECA AB | Method for administering a fluid active substance from a multi-chamber ampoule |
Mar, 2028
(5 years from now) | |
| US8439864 | ASTRAZENECA AB | Device for administering fluid from a multi-chamber ampoule in incremental steps |
Mar, 2028
(5 years from now) | |
|
US8758292
(Pediatric) | ASTRAZENECA AB | Administering apparatus with functional drive element |
May, 2028
(5 years from now) | |
|
US8216180
(Pediatric) | ASTRAZENECA AB | Administering apparatus with functional drive element |
Jul, 2028
(5 years from now) | |
|
US8361972
(Pediatric) | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Sep, 2028
(5 years from now) | |
|
US8439864
(Pediatric) | ASTRAZENECA AB | Device for administering fluid from a multi-chamber ampoule in incremental steps |
Sep, 2028
(5 years from now) | |
|
US9320853
(Pediatric) | ASTRAZENECA AB | Method for administering a fluid active substance from a multi-chamber ampoule |
Sep, 2028
(5 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Patient Population (NPP) | Jul 22, 2024 |
| Pediatric Exclusivity (PED) | Jan 22, 2025 |
Drugs and Companies using EXENATIDE SYNTHETIC ingredient
Market Authorisation Date: 27 January, 2012
Treatment: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin
Dosage: FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS
BYDUREON family patents
11
United States
5
Korea, Republic of
5
European Union
4
China
4
Japan
3
Mexico
3
Poland
2
Germany
2
Brazil
2
EA
2
Lithuania
2
Canada
2
Hungary
2
Denmark
1
Portugal
1
Switzerland
1
Spain
1
Croatia
1
Argentina
1
Austria
1
Peru
1
Taiwan, Province of China
1
Hong Kong
1
Slovenia
1
Chile
1
Australia
1
RS
25. List of Bydureon Bcise drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8361972 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Mar, 2028
(5 years from now) | |
|
US8361972
(Pediatric) | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Sep, 2028
(5 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Patient Population (NPP) | Jul 22, 2024 |
| Pediatric Exclusivity (PED) | Jan 22, 2025 |
Drugs and Companies using EXENATIDE SYNTHETIC ingredient
Market Authorisation Date: 20 October, 2017
Treatment: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin
Dosage: SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS
BYDUREON BCISE family patents
7
United States
5
Korea, Republic of
3
Mexico
2
Brazil
2
China
2
EA
2
Lithuania
2
Canada
2
Japan
2
Hungary
2
European Union
1
Portugal
1
Spain
1
Croatia
1
Argentina
1
Peru
1
Taiwan, Province of China
1
Hong Kong
1
Slovenia
1
Poland
1
Chile
1
Australia
1
RS
1
Denmark
26. List of Canasa drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8436051 | ALLERGAN | Mesalamine suppository |
Jun, 2028
(5 years from now) | |
| US8217083 | ALLERGAN | Mesalamine suppository |
Jun, 2028
(5 years from now) | |
Drugs and Companies using MESALAMINE ingredient
Market Authorisation Date: 05 January, 2001
Treatment: NA
Dosage: SUPPOSITORY;RECTAL
CANASA family patents
7
United States
2
Canada
1
Korea, Republic of
1
Singapore
1
Australia
1
Chile
1
Russia
1
Mexico
1
South Africa
1
Japan
1
China
1
European Union
27. List of Caplyta drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10464938 | INTRA-CELLULAR | Pharmaceutical compositions comprising ((6bR,10aS)-1-(4-fluorophenyl)-4-(3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)butan-1-one or pharmaceutically acceptable salts thereof |
Mar, 2028
(4 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Dec 20, 2024 |
| New Indication (I) | Dec 17, 2024 |
Drugs and Companies using LUMATEPERONE TOSYLATE ingredient
NCE-1 date: 2023-12-21
Market Authorisation Date: 20 December, 2019
Treatment: NA
Dosage: CAPSULE;ORAL
CAPLYTA family patents
13
United States
7
Korea, Republic of
7
Japan
5
Australia
2
Mexico
2
China
2
European Union
1
India
1
Denmark
1
Canada
1
Spain
28. List of Caprelsa drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8067427 | GENZYME CORP | Pharmaceutical compositions comprising ZD6474 |
Aug, 2028
(5 years from now) | |
Drugs and Companies using VANDETANIB ingredient
Market Authorisation Date: 06 April, 2011
Treatment: NA
Dosage: TABLET;ORAL
CAPRELSA family patents
2
United Kingdom
2
Argentina
2
ME
1
Portugal
1
Germany
1
Malaysia
1
Uruguay
1
Russia
1
Spain
1
Brazil
1
Croatia
1
New Zealand
1
Norway
1
Mexico
1
Austria
1
China
1
Taiwan, Province of China
1
Korea, Republic of
1
Hong Kong
1
United States
1
South Africa
1
Japan
1
Canada
1
Cyprus
1
Slovenia
1
Saudi Arabia
1
Ukraine
1
Israel
1
Poland
1
Australia
1
RS
1
Denmark
1
European Union
29. List of Carnexiv drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9770407 | LUNDBECK PHARMS LLC | Parenteral carbamazepine formulation |
Nov, 2028
(5 years from now) | |
| US9629797 | LUNDBECK PHARMS LLC | Parenteral carbamazepine formulation |
Nov, 2028
(5 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Oct 7, 2023 |
Drugs and Companies using CARBAMAZEPINE ingredient
Market Authorisation Date: 07 October, 2016
Treatment: Replacement therapy for oral carbamazepine in adults with partial seizures with complex symptomatology; Replacement therapy for oral carbamazepine in adults with generalized tonic-clonic seizures; Rep...
Dosage: SOLUTION;INTRAVENOUS
CARNEXIV family patents
11
United States
2
Russia
2
Spain
2
Japan
2
European Union
1
Portugal
1
Slovenia
1
New Zealand
1
Poland
1
Australia
1
Brazil
1
Denmark
1
Canada
1
Mexico
1
South Africa
1
China
1
Cyprus
30. List of Colcrys drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8093298 | TAKEDA PHARMS USA | Methods for concomitant administration of colchicine and macrolide antibiotics |
Oct, 2028
(5 years from now) | |
| US8415396 | TAKEDA PHARMS USA | Colchine compositions and methods |
Oct, 2028
(5 years from now) | |
| US8093297 | TAKEDA PHARMS USA | Methods for concomitant administration of colchicine and a second active agent |
Oct, 2028
(5 years from now) | |
| US8097655 | TAKEDA PHARMS USA | Methods for concomitant administration of colchicine and macrolide antibiotics |
Oct, 2028
(5 years from now) | |
| US7964648 | TAKEDA PHARMS USA | Methods for concomitant administration of colchicine and a second active agent |
Oct, 2028
(5 years from now) | |
| US7981938 | TAKEDA PHARMS USA | Colchicine compositions and methods |
Oct, 2028
(5 years from now) | |
| US8415395 | TAKEDA PHARMS USA | Colchicine compositions and methods |
Oct, 2028
(5 years from now) | |
| US7964647 | TAKEDA PHARMS USA | Colchicine compositions and methods |
Oct, 2028
(5 years from now) | |
| US8093296 | TAKEDA PHARMS USA | Methods for concomitant administration of colchicine and macrolide antibiotics |
Oct, 2028
(5 years from now) | |
| US7619004 | TAKEDA PHARMS USA | Methods for concomitant administration of colchicine and macrolide antibiotics |
Dec, 2028
(5 years from now) | |
| US7935731 | TAKEDA PHARMS USA | Methods for concomitant administration of colchicine and macrolide antibiotics |
Dec, 2028
(5 years from now) | |
Drugs and Companies using COLCHICINE ingredient
Market Authorisation Date: 29 July, 2009
Treatment: Method of administering colchicine to familial mediterranean fever patients; Method of treating gout flares; For the treatment and prophylaxis of gout flares & the treatment of familial mediterranean ...
Dosage: TABLET;ORAL
COLCRYS family patents
32
United States
31. List of Combivent Respimat drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7837235 | BOEHRINGER INGELHEIM | Device for clamping a fluidic component |
Mar, 2028
(4 years from now) | |
Drugs and Companies using ALBUTEROL SULFATE; IPRATROPIUM BROMIDE ingredient
Market Authorisation Date: 07 October, 2011
Treatment: NA
Dosage: SPRAY, METERED;INHALATION
COMBIVENT RESPIMAT family patents
2
Germany
2
United States
2
European Union
1
Portugal
1
Spain
1
Brazil
1
Croatia
1
Colombia
1
Egypt
1
Norway
1
Austria
1
Mexico
1
China
1
Korea, Republic of
1
EA
1
South Africa
1
Canada
1
Japan
1
Cyprus
1
Slovenia
1
ME
1
Ukraine
1
Poland
1
Australia
1
Ecuador
1
RS
1
Denmark
32. List of Cubicin drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8003673 | CUBIST PHARMS LLC | Daptomycin for the treatment of biofilm and catheter salvage |
Sep, 2028
(5 years from now) | |
Drugs and Companies using DAPTOMYCIN ingredient
Market Authorisation Date: 12 September, 2003
Treatment: Treatment of the following infections: complicated skin and skin structure infections and staphylococcus aureus bloodstream infections (bacteremia) including those with right-sided infective endocardi...
Dosage: POWDER;INTRAVENOUS
CUBICIN family patents
3
United States
1
Japan
1
Canada
33. List of Dalvance drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6900175 | ALLERGAN | Methods of administering dalbavancin for treatment of bacterial infections |
May, 2028
(5 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | May 23, 2019 |
| New Patient Population (NPP) | Jul 22, 2024 |
| Generating Antibiotic Incentives Now (GAIN) | May 23, 2024 |
Drugs and Companies using DALBAVANCIN HYDROCHLORIDE ingredient
NCE-1 date: 2023-05-24
Market Authorisation Date: 23 May, 2014
Treatment: Treatment of bacterial infections using a two-dose regimen of dalbavancin.
Dosage: POWDER;INTRAVENOUS
DALVANCE family patents
28
United States
5
Japan
5
Australia
4
Korea, Republic of
3
Russia
3
China
3
Hong Kong
3
South Africa
3
Israel
2
New Zealand
2
Norway
2
Mexico
2
Canada
2
European Union
1
Portugal
1
Singapore
1
Spain
1
Brazil
1
Hungary
1
Denmark
34. List of Daurismo drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8431597 | PFIZER | Benzimidazole derivatives |
Jun, 2028
(5 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Nov 21, 2023 |
| Orphan Drug Exclusivity (ODE) | Nov 21, 2025 |
Drugs and Companies using GLASDEGIB MALEATE ingredient
NCE-1 date: 2022-11-21
Market Authorisation Date: 21 November, 2018
Treatment: NA
Dosage: TABLET;ORAL
DAURISMO family patents
4
United States
2
Argentina
2
Peru
2
Lithuania
2
Japan
2
Hungary
1
Portugal
1
Malaysia
1
Uruguay
1
Panama
1
Guatemala
1
Spain
1
Brazil
1
Croatia
1
Costa Rica
1
Colombia
1
IB
1
New Zealand
1
AP
1
Dominican Republic
1
Norway
1
Morocco
1
China
1
Taiwan, Province of China
1
Korea, Republic of
1
Hong Kong
1
Honduras
1
Tunisia
1
EA
1
Nicaragua
1
South Africa
1
Canada
1
Cyprus
1
Slovenia
1
ME
1
Ukraine
1
Israel
1
Cuba
1
Georgia
1
Poland
1
Chile
1
Australia
1
Ecuador
1
RS
1
Denmark
1
Netherlands
1
European Union
35. List of Dexilant drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8871273 | TAKEDA PHARMS USA | Method for producing granules |
Jan, 2028
(4 years from now) | |
Drugs and Companies using DEXLANSOPRAZOLE ingredient
Market Authorisation Date: 30 January, 2009
Treatment: NA
Dosage: CAPSULE, DELAYED RELEASE;ORAL
DEXILANT family patents
4
Japan
3
United States
2
Spain
2
Canada
2
European Union
36. List of Dexilant Solutab drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8871273 | TAKEDA PHARMS USA | Method for producing granules |
Jan, 2028
(4 years from now) | |
|
US8871273
(Pediatric) | TAKEDA PHARMS USA | Method for producing granules |
Jul, 2028
(5 years from now) | |
Drugs and Companies using DEXLANSOPRAZOLE ingredient
Market Authorisation Date: 26 January, 2016
Treatment: NA
Dosage: TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL
DEXILANT SOLUTAB family patents
4
Japan
3
United States
2
Spain
2
Canada
2
European Union
37. List of Differin drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7998467 | GALDERMA LABS LP | Cosmetic/dermatological compositions comprising naphthoic acid compounds and polyurethane polymers |
May, 2028
(5 years from now) | |
Drugs and Companies using ADAPALENE ingredient
Market Authorisation Date: 17 March, 2010
Treatment: Treatment of acne
Dosage: LOTION;TOPICAL
DIFFERIN family patents
4
United States
2
Japan
2
China
1
Korea, Republic of
1
IB
1
France
1
Australia
1
Russia
1
Canada
1
Mexico
1
Argentina
1
Brazil
1
European Union
38. List of Dificid drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8859510
(Pediatric) | CUBIST PHARMS LLC | Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof |
Jan, 2028
(4 years from now) | |
|
US7863249
(Pediatric) | CUBIST PHARMS LLC | Macrolide polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof |
Jan, 2028
(4 years from now) | |
|
US7378508
(Pediatric) | CUBIST PHARMS LLC | Polymorphic crystalline forms of tiacumicin B |
Jan, 2028
(4 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Patient Population (NPP) | Jan 24, 2023 |
| Orphan Drug Exclusivity (ODE) | Jan 24, 2027 |
| Pediatric Exclusivity (PED) | Jul 24, 2023 |
Drugs and Companies using FIDAXOMICIN ingredient
Market Authorisation Date: 27 May, 2011
Treatment: NA
Dosage: TABLET;ORAL
39. List of Doral drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7608616 | GALT PHARMS | Methods for reducing the risk of an adverse drug interaction in a patient suffering from insomnia |
Jun, 2028
(5 years from now) | |
Drugs and Companies using QUAZEPAM ingredient
Market Authorisation Date: 27 December, 1985
Treatment: Method for treating insomnia while reducing the risk of an adverse drug interaction
Dosage: TABLET;ORAL
40. List of Doryx drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8715724 | MAYNE PHARMA | Tabletting process |
Feb, 2028
(4 years from now) | |
Drugs and Companies using DOXYCYCLINE HYCLATE ingredient
Market Authorisation Date: 06 May, 2005
Treatment: NA
Dosage: TABLET, DELAYED RELEASE;ORAL
DORYX family patents
4
United States
3
Australia
41. List of Duetact drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8071130 | TAKEDA PHARMS USA | Solid preparation |
Jun, 2028
(5 years from now) | |
Drugs and Companies using GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE ingredient
Market Authorisation Date: 28 July, 2006
Treatment: NA
Dosage: TABLET;ORAL
DUETACT family patents
3
Japan
1
Malaysia
1
Russia
1
Spain
1
Brazil
1
Croatia
1
Costa Rica
1
New Zealand
1
Norway
1
Argentina
1
Morocco
1
Peru
1
China
1
Taiwan, Province of China
1
Korea, Republic of
1
United States
1
South Africa
1
Canada
1
Ukraine
1
Georgia
1
Australia
1
European Union
42. List of Duzallo drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10183012 | IRONWOOD PHARMS INC | Compounds and compositions and methods of use |
Nov, 2028
(5 years from now) | |
| US8283369 | IRONWOOD PHARMS INC | Compounds and compositions and methods of use |
Nov, 2028
(5 years from now) | |
Drugs and Companies using ALLOPURINOL; LESINURAD ingredient
Market Authorisation Date: 18 August, 2017
Treatment: Treatment of hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a medically appropriate daily dose of allopurinol alone
Dosage: TABLET;ORAL
DUZALLO family patents
25
United States
6
China
6
Japan
5
European Union
4
New Zealand
4
Korea, Republic of
4
EA
4
South Africa
4
Australia
3
Brazil
3
Mexico
3
Taiwan, Province of China
3
Hong Kong
3
Canada
2
Argentina
2
ME
2
Israel
2
Chile
1
Portugal
1
Singapore
1
Malaysia
1
Spain
1
Croatia
1
Colombia
1
Norway
1
Morocco
1
Tunisia
1
Lithuania
1
Cyprus
1
Slovenia
1
Luxembourg
1
Hungary
1
Ukraine
1
Poland
1
RS
1
Ecuador
1
Denmark
43. List of Edarbi drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9066936 | AZURITY | Solid pharmaceutical composition comprising a benzimidazole-7-carboxylate derivative and a pH control agent |
Mar, 2028
(5 years from now) | |
Drugs and Companies using AZILSARTAN KAMEDOXOMIL ingredient
Market Authorisation Date: 25 February, 2011
Treatment: NA
Dosage: TABLET;ORAL
EDARBI family patents
2
Japan
2
Peru
2
United States
1
Taiwan, Province of China
1
Portugal
1
Korea, Republic of
1
New Zealand
1
Chile
1
Australia
1
EA
1
Argentina
1
Mexico
1
Spain
1
Canada
1
China